Trial Profile
A Pilot Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Pharmacodynamics
- 31 Jan 2019 Status changed from active, no longer recruiting to completed.
- 25 Sep 2018 Results published in the Blood Journal.
- 12 Dec 2017 Updated results will be presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.